Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)

<Previous Article In Volume
Next Article In Volume>

The Use of Bosentan in Pulmonary Arterial Hypertension

Authors
Yupaporn Preechagoon1, *, Samaporn Kawboot1, Supabhorn Onsanit2
1Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
2Pharmacy Department, Queen Sirikit Heart Center of the Northeast, Khon Kaen, Thailand
*Corresponding author. Email: yuppre@kku.ac.th
Corresponding Author
Yupaporn Preechagoon
Available Online 14 December 2022.
DOI
10.2991/978-94-6463-050-3_6How to use a DOI?
Keywords
Bosentan 1; pulmonary arterial hypertension 2
Abstract

The main class of drugs specific treatment for pulmonary arterial hypertension (PAH) were calcium channel blocker, sildenafil, bosentan, beraprost and iloprost. Bosentan is a competitive, specific dual receptor (ET-A and ET-B) antagonist. The aim of this study was to investigate the pattern, reason, effect, and adverse drug reaction of bosentan in PAH patients at Queen Sirikit Heart Center of the Northeast, Thailand. A retrospective study had been collected the data from medical record and electronic database for 3 years. The results showed from the 16 patients with PAH, 7 patients concluded in the criteria, but only medical record of 5 patients could be accessed. The 4 patients (80%) used in monotherapy and 1 patient (20%) in combination with sildenafil. The reason for prescribing, 3 patients (60%) failed to use sildenafil for more than three months and 2 patients (40%) used for first line treatment in WHO FC II. After one-year treatment, 4 patients (80%) treated with bosentan had improved WHO FC and improved 6MWD; the mean difference before and after one year was 40 m (p = 0.157). In addition, most patients did not have any adverse drug reaction. Most of prescription pattern of bosentan was monotherapy and used in patients who failed from sildenafil. Bosentan has been shown to improve WHO FC and 6MWD in patients with PAH.

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)
Series
Atlantis Highlights in Chemistry and Pharmaceutical Sciences
Publication Date
14 December 2022
ISBN
10.2991/978-94-6463-050-3_6
ISSN
2590-3195
DOI
10.2991/978-94-6463-050-3_6How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Yupaporn Preechagoon
AU  - Samaporn Kawboot
AU  - Supabhorn Onsanit
PY  - 2022
DA  - 2022/12/14
TI  - The Use of Bosentan in Pulmonary Arterial Hypertension
BT  - Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)
PB  - Atlantis Press
SP  - 55
EP  - 62
SN  - 2590-3195
UR  - https://doi.org/10.2991/978-94-6463-050-3_6
DO  - 10.2991/978-94-6463-050-3_6
ID  - Preechagoon2022
ER  -